Mavacamten, a cardiac myosin inhibitor received FDA approval in April 2022 for treating symptomatic obstructive hypertrophic cardiomyopathy (HCM) of New York Heart Association (NYHA) class II-III and improving functional capacity while relieving symptoms. Mavacamten is a selective cardiac myosin inhibitor that acts on myosin heads leading to activation of the actin state, thereby reducing excessive myosin actin cross-bridge formations – the hallmark for HCM, and inducing an energy-sparing, super relaxed state leading to reduce cardiac-filling pressure and Left ventricular outflow tract (LVOT) obstruction. The safety and efficacy of the drug were evaluated in phase 3, randomized, double-blinded, placebo-controlled, multicentre, international, parallel-group trial in 251 adults with symptomatic NYHA class II and III obstructive HCM.
The study was named EXPLORER-HCM (Table 1). Table 1.…
